## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
nours per response						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)									•				
Name and Address of Reporting Person *  Romano Sarah				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X Officer (give title below) Other (specify below)  Chief Financial Officer					
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 08/06/2019							Chie	et Financial (	Officer		
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City	)	(State)	(Zip)	Table I - Non-Derivative Securities Acqui						ired, Disp	osed of, or l	Beneficially	Owned		
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, is any (Month/Day/Year	if Code (Instr. 8)		(A)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		ollowing	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Co	ode	V	Amou	nt (A) or (D)	Price				(I) (Instr. 4)	(111311. 4)
Common	Stock		08/06/2019		I	F		1,649	9 D	\$ 0.21	260,464			D	
Reminder:	Report on a s	separate line fo		Derivative Securit	ies Ac	quire	Pers cont the f	ons when the constant of the c	ho respo in this fo splays a of, or Be	orm ar curre	e not requently valid	OMB con	formation spond unle trol numbe	SS	C 1474 (9-02)
				e.g., puts, calls, w		ts, op								2 42	44.37
Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/	Execution Da Year) any	4. Transaction Code (Instr. 8)	5. Numb of Deriva Securi Acqui (A) or Dispo of (D) (Instr. 4, and	ative ities ired seed ) . 3,	and Expiration Date (Month/Day/Year)  All Use (Ii 4)		Am Und Sec	Title and ount of derlying urities str. 3 and	8. Price of Derivative Security (Instr. 5)		Ownersh Form of Derivatir Security Direct (I or Indire	Beneficia Ownershi (Instr. 4)	
				Code V	(A)	(D)	Date Exer	e rcisable	Expiration Date	On Titl	Amount or e Number of Shares				

# **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Romano Sarah C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			Chief Financial Officer				

### **Signatures**

/s/ Sarah Romano	08/07/2019
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.